Allen Zderad lost his vision, but due to a bionic eye implant from a clinical trial, he regained the ability to see human forms and outlines of objects. The implant sends light wave signals to the optic nerve, compensating for a damaged retina.
Yet another next-generation sequencing startup has disclosed that it's won financing. Lifecode, formerly known as Silicon Valley Biosystems, has garnered a $20.5 million Series A round from investors including Sequoia Capital, The Mayo Clinic and Mayo Ventures.
Minnesota's Mayo Clinic is suing one of its former top executives for misappropriation of trade secrets as part of a plan to work for competitor Quest Diagnostics following a false retirement.
Researchers may have found the key to destroying the amyloid-β clumps long associated with Alzheimer's disease, which could spur new approaches to drug discovery in a field that has seen more than its share of failures.
An interesting development in this age of Irish-fueled tax inversion deals, the Mayo Clinic and Enterprise Ireland have begun a 5-year collaboration to advance med tech innovation.
Biotech Seres Health has raised a quick $10 million B round to support its work in microbiome R&D, appending a partnership with the Mayo Clinic as it advances an infectious disease treatment.
The blood-brain barrier is the body's way of keeping harmful substances away from the brain, but it's also a daunting obstacle for drug delivery experts looking to send treatments to the organ. Now, researchers at the Mayo Clinic have developed a synthetic peptide carrier to shuttle small molecules past the barrier and into the brain.
Sanovas, a devicemaker specializing in microinvasive surgery for the lungs, joined forces with the Mayo Clinic to market its outpatient treatment for asthma that relaxes the muscles that constrict the airways.
A technique known as metabolomics may enable an Alzheimer's disease blood test diagnosis before patients start displaying symptoms, Mayo Clinic scientists have concluded.
An experimental drug designed to block an overactive protein in kidney cancer may provide a more targeted approach to treating the common cancer and could eventually be used as a therapy for other types of the disease.